Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | 2C20H38N6O4.H2O4S |
| Molecular Weight | 951.186 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 6 / 6 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OS(O)(=O)=O.CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C=O.CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C=O
InChI
InChIKey=CIPMKIHUGVGQTG-VFFZMTJFSA-N
InChI=1S/2C20H38N6O4.H2O4S/c2*1-12(2)9-16(24-14(5)28)19(30)26-17(10-13(3)4)18(29)25-15(11-27)7-6-8-23-20(21)22;1-5(2,3)4/h2*11-13,15-17H,6-10H2,1-5H3,(H,24,28)(H,25,29)(H,26,30)(H4,21,22,23);(H2,1,2,3,4)/t2*15-,16-,17-;/m00./s1
| Molecular Formula | C20H38N6O4 |
| Molecular Weight | 426.5535 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 3 / 3 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
| Molecular Formula | H2O4S |
| Molecular Weight | 98.078 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Leupeptin is produced by various species of Actinomycetes. It strongly inhibits proteolysis by plasmin, trypsin and papin. Leupeptin is well absorbed through oral route. Leupeptin has been known to cause various neuropathological changes in vivo resembling those of aging or neurodegenerative processes in the human brain, including the accumulation of neuronal processes and neuronal cytoskeletal abnormalities leading to neurofibrillary tangle (NFT)-like formations. In in vitro experiments, leupeptin protects the heart from myocardial stunning. Leupeptin was found to inhibit tumorigenesis in mouse skin induced by a single, noncarcinogenic dose of 7,12- dimethylbenz(a)anthracene followed by repeated application of croton oil. Tumors that had already been induced were scarcely affected by leupeptin.
CNS Activity
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: Protein methylesterase (rat) |
35.0 nM [Ki] | ||
Target ID: Thrombokinase (Bos taurus) |
|||
Target ID: CHEMBL2366 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
|||
| Preventing | Unknown Approved UseUnknown |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Drug-induced lysosomal changes and nephrotoxicity in rats. | 1978 Nov |
|
| Inhibition of the growth of human coronavirus 229E by leupeptin. | 1985 Feb |
|
| Efficacy of serine protease inhibitors against Cryptosporidium parvum infection in a bovine fallopian tube epithelial cell culture system. | 1996 Aug |
|
| Cryptosporidium parvum metalloaminopeptidase inhibitors prevent in vitro excystation. | 1996 Dec |
|
| Characterization of cytochrome P4502E1 turnover in transfected HepG2 cells expressing human CYP2E1. | 1997 May 1 |
|
| Inhibition of proteolysis by a cyclooxygenase inhibitor, indomethacin. | 2000 Nov |
|
| Proteasomal degradation of caspase-6 in 17beta-estradiol-treated neurons. | 2004 May |
|
| Activation and enzymatic characterization of recombinant human kallikrein 8. | 2006 Jun |
|
| Transforming growth factor-beta1 inhibits all-trans retinoic acid-induced apoptosis. | 2006 May |
|
| Regulation of adipocyte lipolysis by degradation of the perilipin protein: nelfinavir enhances lysosome-mediated perilipin proteolysis. | 2007 Jul 27 |
|
| Defective hepatocyte aquaporin-8 expression and reduced canalicular membrane water permeability in estrogen-induced cholestasis. | 2007 Mar |
|
| 2,2',4,4',5,5'-hexachlorobiphenyl (PCB 153) induces degradation of adherens junction proteins and inhibits beta-catenin-dependent transcription in liver epithelial cells. | 2009 Jun 16 |
|
| Molecular modeling: a search for a calpain inhibitor as a new treatment for cataractogenesis. | 2011 Nov 10 |
|
| Urban particulate matter activates Akt in human lung cells. | 2012 Jan |
Patents
Sample Use Guides
Rat: 0.2 ml (1 mg/ml) was administrated five times at 2-h intervals per day.
Route of Administration:
Oral
The activity of the skin TAME (p-toluene-sulfonyl-L-arginine methyl ester) esterase had increased almost 2.5 times at 24 hr after 0.3% croton oil treatment. The TAME esterase activity was significantly inhibited by addition of leupeptin, 0.1 mg/ml, and it was progressively inhibited by higher concentrations of leupeptin. The activity was less than 10% of the control in the presence of leupeptin, 2.5 mg/ml.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 07:38:16 GMT 2023
by
admin
on
Sat Dec 16 07:38:16 GMT 2023
|
| Record UNII |
05V9Y5208M
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
05V9Y5208M
Created by
admin on Sat Dec 16 07:38:16 GMT 2023 , Edited by admin on Sat Dec 16 07:38:16 GMT 2023
|
PRIMARY | |||
|
2733491
Created by
admin on Sat Dec 16 07:38:16 GMT 2023 , Edited by admin on Sat Dec 16 07:38:16 GMT 2023
|
PRIMARY | |||
|
103476-89-7
Created by
admin on Sat Dec 16 07:38:16 GMT 2023 , Edited by admin on Sat Dec 16 07:38:16 GMT 2023
|
PRIMARY | |||
|
90629
Created by
admin on Sat Dec 16 07:38:16 GMT 2023 , Edited by admin on Sat Dec 16 07:38:16 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
SOLVATE->ANHYDROUS |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
